• WQ-C-401 Targets PDGFR in Experimental PAH

  2026-09-15

  The reference study identifies WQ-C-401 as a selective PDGFR inhibitor that suppresses PDGF-driven signaling, pulmonary vascular remodeling, and right-heart stress in monocrotaline-induced pulmonary arterial hypertension. Its combination of kinome profiling, cellular assays, and in vivo pathology provides a useful framework for evaluating PDGFR-directed therapies beyond pressure reduction alone.

• BFH772 (VEGFR2 inhibitor): Workflow Guide

  2026-09-15

  BFH772 is a selective small-molecule VEGFR2 inhibitor for kinase, cellular, and angiogenesis studies that require an organic-solvent-compatible compound. Its water insolubility, storage constraints, and absence of directly matched paper evidence require fresh solution preparation, vehicle controls, and independent assay validation; it is not appropriate for protocols that require a water-soluble reagent or broad-spectrum kinase inhibition.

• SFRP1, Wnt/β-Catenin, and Oral Fibrosis

  2026-09-14

  A 2024 study links reduced SFRP1 with neutrophil infiltration, collagen accumulation, and Wnt/β-catenin activation in arecoline-induced oral submucous fibrosis. Its combination of tissue correlation, SFRP1 overexpression, and pathway-activation reversal experiments provides a useful mechanistic framework for studying inflammatory fibrosis in oral disease.

• RRP Restores Lipid Metabolism in HIRI

  2026-09-14

  This Journal of Ethnopharmacology study identifies restoration of hepatocyte cholesterol handling as a central mechanism by which Radix Rehmanniae Praeparata extracts reduce hepatic ischemia-reperfusion injury. Using mouse HIRI models, oleate–palmitate-loaded hepatocytes, transcriptomics, and pathway-directed inhibition, the authors connect AMPK activation with reduced SCAP-SREBP2 cholesterol synthesis and enhanced LXRα-dependent cholesterol efflux.

• 17-AAG (Tanespimycin) Cancer Research Workflow

  2026-09-13

  17-AAG (Tanespimycin) provides a practical route to connect HSP90 client-protein loss with viability, apoptosis, and pathway-level readouts across cancer models. This workflow also shows how findings on regulated protein secretion can improve assay controls without overstating an unvalidated antiviral application.

• Catharanthus ‘Timebomb’ Defense Against Herbivores

  2026-09-12

  The reference study shows how Catharanthus roseus combines spatially separated alkaloid precursors with HIVE-dependent transcriptional reprogramming to defend against chewing herbivores while reallocating resources during cold stress. Its integrated insect bioassays, transcriptomic analyses, promoter assays, and protein–protein interaction studies provide a mechanistic framework for inducible chemical defense and stress prioritization.

• Telmisartan and the Next Era of Cardiac Hypertrophy

  2026-09-11

  Telmisartan is more than an angiotensin II receptor antagonist: it is a strategic upstream perturbation for dissecting how AT1R signaling connects with maladaptive remodeling. This thought-leadership guide integrates Telmisartan with emerging RIP3/CaMKII biology to help translational researchers design more informative cardiac hypertrophy studies.

• SmCPK20–SmWRKY2 Control of Tanshinone Synthesis

  2026-09-11

  The reference study identifies a post-translational mechanism connecting jasmonate perception, calcium-dependent protein kinase activity, and tanshinone biosynthesis in Salvia miltiorrhiza. Its central finding is that SmCPK20 phosphorylates SmWRKY2 at Thr-256, strengthening SmWRKY2 activation of SmCPS1 after jasmonate-induced release from SmJAZ3 repression.

• CHIR 99021 Trihydrochloride for Organoids

  2026-09-10

  Use CHIR 99021 trihydrochloride as a tunable GSK-3 inhibitor for organoid expansion, stem cell maintenance and differentiation, and metabolic assay design. This guide connects concentration screening, organoid engineering, and glucose-related applications while separating product-backed parameters from workflow starting points.

• α2-adrenergic receptor agonist Workflows

  2026-09-10

  Build reproducible α2-adrenergic receptor signaling assays with a DMSO-soluble small molecule suited to receptor pharmacology, immune profiling, and hydrogel-based osteosarcoma recurrence research. The workflow separates direct tumor-cell effects from immune-mediated responses and includes practical controls for solubility, stability, timing, and formulation quality.

• Letrozole: From Aromatase Biology to Assay Design

  2026-09-09

  Letrozole is a non-steroidal aromatase inhibitor whose value in research extends beyond simple enzyme blockade. This article connects aromatase mechanism, endocrine biomarker logic, and cross-domain assay design while clarifying how clinical endocrine-therapy evidence can guide experimental decisions.

• How p38α Conformation Drives Dephosphorylation

  2026-09-09

  The reference study shows that some ATP-site kinase inhibitors do more than block p38α catalytic activity: they reshape the activation loop so WIP1 can dephosphorylate it more efficiently. Biochemical and X-ray structural evidence establishes a dual-action mechanism that may guide more selective strategies for controlling kinase signaling.

• Y-27632: Selective ROCK Inhibitor Guide

  2026-09-08

  Y-27632 is a selective ROCK inhibitor that targets ROCK1 and ROCK2 through reversible, ATP-competitive binding. Its strongest research uses include cell stress fiber disruption, cytoskeletal dynamics modulation, and controlled ROCK signaling pathway research, while tissue-engineering evidence supports further mechanistic study rather than clinical use.

• Ceramides Promote RGNNV Infection Through Autophagy

  2026-09-08

  A 2026 Journal of Virology study uses global lipidomics and functional perturbation to show that ceramide accumulation supports red-spotted grouper nervous necrosis virus replication. The work connects capsid-protein activity, three ceramide-producing pathways, and autophagy, providing a mechanistic framework for studying viral nervous necrosis in aquaculture.

• Separating Growth Inhibition from Cell Death in Cancer

  2026-09-07

  Hannah Schwartz’s dissertation shows that relative viability and fractional viability capture different components of an in vitro anticancer response. Its central practical contribution is a framework for analyzing proliferative arrest, cell killing, and their timing as related but non-interchangeable outcomes.

8107 records 1/541 page Next 12345 下5页 Last page